FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
|Slideshows|July 29, 2022
Monkeypox Quick Take: What do Americans Think, Believe, Fear?
Author(s)Grace Halsey
A new survey of monkeypox outbreak perceptions among US adults offers primary care clinicians a quick take on what their patients may be thinking.
Advertisement
The monkeypox virus outbreak is causing significant concern in some parts of the country, most notably in New York where the state today declared monkeypox an “Imminent Threat to Public Health” and in San Francisco where the mayor announced a “legal state of emergency” around the outbreak.
What do Americans think about the monkeypox virus and the outbreak at this stage? Are false beliefs beginning to coalesce around misinformation already in wide circulation? Are people afraid of contracting monkeypox?
The Annenberg Public Policy Center posted findings today from a survey conducted July 12-18, 2022 of more than 1500 Americans that queried these topics and more. Get a quick take on the results in the slides below.
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
Advertisement
Advertisement
Trending on Patient Care Online
1
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
2
5 FDA Decisions for Primary Care to Know from September 2026
3
Fezolinetant Linked to 2.6 Fewer Nighttime Awakenings in Women With Menopausal VMS
4
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
5